News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Inspire Pharmaceuticals, Inc. (ISPH) And FAES Farma Announce Licensing Agreement For New Oral Antihistamine To Target Allergy Market In United States And Canada; Up to $89 Million


11/1/2006 12:09:26 PM

DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) and FAES Farma, S.A. (IBEX: FAE) announced today the signing of a licensing agreement for the U.S. and Canadian development and commercialization of bilastine, a Phase 3 oral antihistamine compound for the treatment or prevention of allergic rhinitis, a condition affecting approximately 40 million people in the United States.

Read at BioSpace.com
Read at AP

Related News

comments powered by Disqus
BioSpace.com
AP
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES